Skip to main content

Table 5 Additional known-group comparisons of the Taiwan Chinese EORTC QLQ-C30 and QLQ-CR29

From: Validation of the Taiwan Chinese version of the EORTC QLQ-CR29 to assess quality of life in colorectal cancer patients

Scale

Stoma

 

Surgery

 

Adjuvant therapy

 

Without stomy

With stomy

P-value&

Minimally invasive

Laparotomy

P-value&

Without adjuvant therapy

With adjuvant therapy

P-value&

n = 97

n = 11

 

n = 61

n = 42

 

n = 38

n = 65

 

QLQ-C30 function

 QL2

64.1

62.1

0.706

64.3

66.0

0.793

65.7

62.9

0.610

 PF

81.9

81.8

0.516

83.0

82.2

0.447

84.3

80.5

0.143

 RF

80.7

69.7

0.095

82.8

78.9

0.315

84.2

77.0

0.137

 EF

79.9

89.4

0.090

80.6

83.7

0.482

84.5

79.0

0.136

 CF

78.6

89.4

0.059

78.9

82.5

0.473

81.5

78.7

0.514

 SF

79.1

69.7

0.182

83.6

72.8

0.012

86.0

73.9

0.009

QLQ-C30 symptom

 FA

30.8

26.3

0.591

31.1

27.6

0.805

27.3

32.0

0.353

 NV

7.4

15.2

0.124

5.2

11.5

0.028

4.7

10.1

0.064

 PA

16.7

21.2

0.521

15.8

17.9

0.633

17.5

16.9

0.871

 DY

13.2

12.1

0.995

13.1

11.4

0.977

12.3

13.5

0.966

 SL

26.3

9.1

0.034

28.2

19.8

0.161

27.9

22.7

0.400

 AP

16.2

18.2

0.963

14.2

16.7

0.897

12.0

18.8

0.114

 CO

25.0

18.2

0.569

26.2

22.8

0.625

25.6

23.5

0.811

 DI

22.8

27.3

0.380

25.0

17.1

0.380

23.4

23.2

0.830

 FI

15.1

15.2

0.662

12.2

16.3

0.272

10.8

17.4

0.124

QLQ-CR29 function

 BI

86.4

88.9

0.908

88.3

85.4

0.455

89.8

84.9

0.094

 ANX

62.1

69.7

0.377

62.7

65.9

0.513

62.3

63.2

0.880

 WEI

75.2

69.7

0.289

74.6

75.6

0.969

78.9

72.1

0.103

 SEXF

17.8

15.2

0.542

16.7

18.4

0.380

20.6

15.9

0.311

QLQ-CR29 symptom

 UF

21.1

25.8

0.498

20.9

20.3

0.852

21.1

21.9

0.933

 BMS

11.6

12.1

0.712

10.6

9.8

0.792

11.8

11.6

0.923

 SF2

19.1

33.3

0.053

19.6

19.4

0.878

24.3

18.5

0.067

 UI

6.4

6.1

0.808

5.1

6.5

0.133

3.5

8.0

0.297

 DY2

2.8

0.0

0.322

1.7

3.3

0.375

0.9

3.5

0.151

 AP2

13.8

15.2

0.866

13.0

13.0

0.668

14.9

13.4

0.990

 BP

8.7

21.2

0.089

6.9

14.2

0.040

7.2

11.6

0.173

 BF

20.1

24.2

0.447

19.5

18.7

0.606

25.4

17.7

0.111

 DM

28.7

30.3

0.664

28.2

27.6

0.940

24.6

31.3

0.100

 HL

17.8

15.2

0.690

14.4

23.3

0.108

4.5

24.7

0.000

 TA

10.8

15.2

0.891

9.0

15.8

0.100

5.4

14.4

0.056

 FL

21.9

21.2

0.928

21.8

20.2

0.737

22.5

21.4

0.913

 FI2

9.3

21.2

0.025

9.8

8.8

0.944

8.1

12.0

0.654

 SS

6.5

21.2

0.025

7.0

8.1

0.777

5.6

9.7

0.181

 EMB

12.7

21.2

0.089

14.4

9.9

0.685

9.9

15.9

0.275

 STO

 

15.0

 

0.0

4.8

0.499

0.0

5.6

0.831

 IMP

21.8

9.5

0.142

20.0

20.5

0.691

19.3

20.8

0.708

 DYS

9.5

8.3

0.921

7.7

12.1

0.450

2.4

13.3

0.119

  1. QL2 global health/quality of life, PF physical function, RF role function, EF emotion function, CF cognitive function, SF social function, FA fatigue, NV nausea/vomiting, PA pain, DY dyspnea, SL insomnia, AP appetite loss, CO constipation, DI diarrhea, FI financial difficulty, BI body image, ANX anxiety, WEI weight, SEXF sexual interest, UF urinary frequency, BMS blood and mucus in stool, SF2 stool frequency, UI urinary incontinence, DY2 dysuria, AP2 abdominal pain, BP buttock pain, BF bloating, DM dry mouth, HL hair loss, TA taste, FL flatulence, FI2 faecal incontinence, SS sore skin, EMB embarrassment, STO stoma care problem, IMP importance, DYS dyspareunia
  2. &Wilcoxon rank sum test. P-values in boldface indicated significant between-group difference in quality of life scores
  3. Quality of life scores presented as medium (interquartile range)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us